Close Menu
August 25, 2020

Liquid Biopsy-based Molecular Risk Stratification of ALK-mutated Lung Cancer Patients

Genome Webinar

Division of Cancer Genome Research,
German Cancer Consortium and German Cancer Research Center

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.

The presentation will discuss a recent study addressing the longitudinal genotyping of circulating cell-free DNA (cfDNA) from patients with ALK rearrangements by combining panel-based deep sequencing with shallow whole-genome sequencing.

The results suggest that this liquid biopsy approach might be able to improve the care of ALK-mutated NSCLC patients through early detection of resistance mutations and indications of disease progression.

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

Jul
16

Join this webinar to learn how spatial resolution of gene expression in tumor tissue reveals new insights in biomarker discovery and therapeutic response. 

Jul
23

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.

Aug
25

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.